Patents Assigned to Novo Nordisk
  • Human coagulation factor VII variants
    Publication number: 20050204406
    Abstract: The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305).
    Type: Application
    Filed: April 21, 2005
    Publication date: September 15, 2005
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Egon Persson, Ole Olsen
  • Combined use of a GLP-1 compound and another drug for treating dyslipidemia
    Patent number: 6939853
    Abstract: Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: September 6, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Lotte Bjerre Knudsen, Johan Selmer
  • Compounds with growth hormone releasing properties
    Patent number: 6939880
    Abstract: Compounds of peptide mimetic nature having the general formula I wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: September 6, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Bernd Peschke, Jesper Lau, Behrend Friedrich Lundt, Michael Ankersen, Brett Watson, Kjeld Madsen
  • Atraumatic insertion of a subcutaneous device
    Patent number: 6936006
    Abstract: The invention relates to a concept for placing a subcutaneous device such as a sensor at a selected site within the body of a patient, e.g. to obtain blood glucose readings. In a first aspect, an insertion needle comprises an oblong needle body and a distal end portion, the distal end portion having a pointed distal tip allowing the needle to be introduced subcutaneously and a distally facing generally smooth surface, the body comprising along a portion thereof a longitudinal groove adapted to at least partially accommodate the subcutaneous device. In a second aspect, a combination of an insertion needle and a subcutaneous device form an oblong body portion and a distal end portion formed by either of the members or in combination by the two members, the distal end portion having a pointed distal tip and a distally facing generally smooth surface.
    Type: Grant
    Filed: March 19, 2003
    Date of Patent: August 30, 2005
    Assignee: Novo Nordisk, A/S
    Inventor: Mads C. Sabra
  • Method for making recombinant proteins
    Patent number: 6933136
    Abstract: The invention provides nucleic acid molecules and vector constructs comprising scaffold/matrix attachment regions and methods of using such scaffold/matrix attachment regions for the industrial production of recombinant proteins and polypeptides.
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: August 23, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Ruth Buemann Simesen, Anette Amstrup Pedersen, Steffen Faisst, Jan Eric Jensen, Dietmar Weilguny
  • Non-peptide GLP-1 agonists
    Patent number: 6927214
    Abstract: Novel non-peptide GLP-1 agonists, pharmaceutical compositions comprising them, use of the non-peptide GLP-1 agonists for the preparation of pharmaceutical compositions and methods for the treatment and/or prevention of disorders and diseases wherein an activation of the human GLP-1 receptor is beneficial, especially metabolic disorders such as IGT, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: January 14, 2000
    Date of Patent: August 9, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Min Teng, Larry Kenneth Truesdale, Dilip Bhumralkar, Dan Kiel, Michael D. Johnson, Christine Thomas, Anker Steen Jorgensen, Peter Madsen, Preben Houlberg Olesen, Liselotte Bjerre Knudsen, Ingrid Vivika Petterson, Johannes Cornelis de Jong, Carsten Behrens, Janos Tibor Kodra, Jesper Lau
  • Human tissue factor antibodies
    Publication number: 20050169927
    Abstract: The present invention relates to isolated fully human antibodies that immunoreacts with human tissue factor (TF) to inhibit the binding of coagulation factor VIIa (FVIIa).
    Type: Application
    Filed: March 31, 2005
    Publication date: August 4, 2005
    Applicant: Novo Nordisk A/S
    Inventors: Per-Ola Freskgaard, Jes Clausen, Brit Sorensen, Marianne Kjalke
  • Compounds with growth hormone releasing properties
    Patent number: 6919315
    Abstract: Disclosed are compounds of formula I formula I wherein R1, R2, R5, R6, R7, R8, G, J, L, M, a, b, c, d, e, and f are as defined in the specification, and compositions containing them. These compounds are useful for treating medical disorders resulting from a deficiency in growth hormone.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: July 19, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Birgit Richter, Thomas Hansen Kruse, Michael Ankersen, Lutz Richter
  • Steroid compounds, use of these compounds for the preparation of meiosis-regulating medicaments and method for the preparation of these compounds
    Patent number: 6916921
    Abstract: The present invention relates to steroid compounds of general formula X, which may advantageously be employed to stimulate meiosis in human oocytes, the steroid being specifically characterized by amino nitrogen bonded to C17 of the steroid skeleton via a spacer A.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: July 12, 2005
    Assignees: Schering AG, Novo Nordisk D/S
    Inventors: Thorsten Blume, Peter Esperling, Christa Hegele-Hartung
  • Human coagulation factor VII polypeptides
    Patent number: 6911323
    Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: June 28, 2005
    Assignee: Novo Nordisk Healthcare A/G
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Substituted imidazoles, their preparation and use
    Patent number: 6908926
    Abstract: Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: June 21, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Knud Erik Andersen, Tine Krogh Jørgensen, Bernd Peschke, Birgitte Schjellerup Wulff, Ingrid Pettersson, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Müller, Bernd Krist
  • Substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines
    Patent number: 6906060
    Abstract: Novel substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
    Type: Grant
    Filed: June 3, 2003
    Date of Patent: June 14, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Bernd Peschke, Rolf Hohlweg
  • Human coagulation factor VII variants
    Patent number: 6905683
    Abstract: The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305).
    Type: Grant
    Filed: May 3, 2001
    Date of Patent: June 14, 2005
    Assignee: Novo Nordisk Healthcare A/G
    Inventors: Egon Persson, Ole Hvilsted Olsen
  • Factor VII glycoforms
    Patent number: 6903069
    Abstract: The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: June 7, 2005
    Assignee: Novo Nordisk Health Care A/S
    Inventors: Hans Kurt Pingel, Niels Kristian Klausen
  • Automatic injection device with reset feature
    Patent number: 6899699
    Abstract: The present invention relates to a dose setting and expelling device comprising a drive member and a dose setting mechanism which simultaneously sets a given dose and stores the energy necessary for a subsequently driving the drive member in order to expel a dose of medicine from an injection device. According to the invention the dose setting mechanism allows adjustment in both directions, such that a given set dose can be reduced or cancelled by reversing the input motion, typically by rotating a setting member backwardly, this in contrast to the known devices which either requires an additional release mechanism or which cannot be reversed at all.
    Type: Grant
    Filed: January 2, 2002
    Date of Patent: May 31, 2005
    Assignee: Novo Nordisk A/S
    Inventor: Christian Enggaard
  • Medication delivery device
    Patent number: 6893415
    Abstract: A medication delivery device comprising a system that is able to sense if the delivery device is in actual physical contact with a human being or if the delivery device has been abandoned. The system comprises an electronic control and a touch sensitive switch preferably formed as a part of the housing of the medication delivery device. The housing can be divided into two parts each constituting separate electrical conductors being spaced apart from each other by an insulating material. When the two parts a temporarily bridged e.g. by the skin of a human being a direct current path between the parts are created, which can provide an electrical signal at the electronic control. When a dose has been set, absence of the signal will cause the electronic control to cancel the set dose and to sound an alarm.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: May 17, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Mads Koerstz Madsen, Jens Munk
  • Growth hormone crystals and a process for production of these GH-crystals
    Patent number: 6894023
    Abstract: A process for producing cation crystals of growth hormone or growth hormone derivatives, as well as growth hormone and growth hormone derivatives. The process of producing the growth hormone crystals includes the steps of (a) adding cations of inorganic or organic nature and an organic solvent or a mixture of inorganic solvents at a pH between 5.0 and 6.8 to a solution of growth hormone or derivatives. (b) growing growth hormone crystals at a temperature from about 0 to 30° C. and (c) isolating the cation crystals.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: May 17, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Flemming Junker, Claus Friis Theisen
  • Meiosis regulating compounds
    Publication number: 20050101573
    Abstract: Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
    Type: Application
    Filed: December 16, 2004
    Publication date: May 12, 2005
    Applicants: Novo Nordisk A/S, Schering AG
    Inventors: Peter Faarup, Frederick Gronvald, Thorsten Blume, Anthony Murray, Jens Breinholt
  • Glucagon antagonists/inverse agonists
    Patent number: 6875760
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Grant
    Filed: August 30, 2002
    Date of Patent: April 5, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Inge Thøger Christensen, Behrend Frederik Lundt, Ulla Grove Sidelmann, Henning Thøgersen, Anthony L. Ling, Michael Bruno Plewe, Larry Kenneth Truesdale, Anker Steen Jøgensen, Janos Tibor Kodra, Shenghua Shi
  • Halo sulfonyl aryl boronates
    Patent number: 6872849
    Abstract: The present invention relates to halo sulfonyl aryl boronates of the general formula (I): wherein Arylene designates a carbocyclic or heterocyclic, aromatic ring system comprising 1-3 rings; R1, R2 and R3 are, independently, hydrogen, C1-6alkyl, C1-6alkoxy, halogen, nitro, cyano or phenyl; X is fluoro, chloro or bromo; and Y is a boroxine moiety attached via a bond from Arylene to one of the boron atoms of a boroxine ring which ring has a group of the formula -Arylene(R1)(R2)(R3)SO2X, wherein Arylene, R1, R2, R3 and X are as defined above, at each of the other two boron atoms of the boroxine ring, or Y is a boronic acid group or a boronic ester group. The invention also relates to the preparation of the compounds of formula (I) and to their use in organic synthesis.
    Type: Grant
    Filed: October 30, 2003
    Date of Patent: March 29, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Per Vedso, Preben Houlberg Olesen, Thomas Hoeg-Jensen